Life science start-up Actome receives seed funding

The Freiburg-based start-up is developing an analysis tool for proteins. With the help of the start-up financing, it wants to bring the product to market maturity.

The Freiburg-based life science company Actome has received seed funding. Founded in 2017, the start-up previously conducted its research from the University of Freiburg. Now the biotech investment house B.Value from Düsseldorf and other unnamed investors are putting money into the start-up. The amount of the start-up financing is not disclosed. The money is intended to help Actome build up a business and develop its first products to market maturity.

Actome develops analysis tools for the life sciences. The first products will help researchers to measure proteins and protein interactions in biological samples with unprecedented sensitivity and specificity. Proteins control and direct biological processes through their interactions - the so-called interactome - through which they determine our health and well-being. Actome's technology will enable researchers to understand these interactions even better. This will change medical diagnostics in an unprecedented way, says Csaba Jeney, co-founder and CEO, about the technology he has invented and patented. If this succeeds, it will be possible to develop more personalized medical products than before.